Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Nov
08
Today In Oncology
Impact of Concomitant Noncancer Medications on Outcomes in Breast Cancer
NCCN Guidelines to Be Integrated Into OpenEvidence Medical AI Platform
Adding an Investigational Monoclonal Antibody to Ibrutinib May Allow Patients With CLL to Discontinue Daily Treatment
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
Armando Giuliano Honored With 2025 William L. McGuire Memorial Lecture Award
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo